WAM
VRTX icon

Wolverine Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Wolverine Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,600
Closed -$644K – 1786
2024
Q4 		$644K Hold
1,600
– – 0.01% 809
2024
Q3 		$744K Sell
1,600
-3,900
-71% -$1.87M 0.01% 775
2024
Q2 		$2.58M Buy
5,500
+2,600
+90% +$1.13M 0.03% 445
2024
Q1 		$1.21M Buy
+2,900
New +$1.23M 0.01% 598
2017
Q4 		– Sell
-50,000
Closed -$7.6M – 1612
2017
Q3 		$7.6M Buy
+50,000
New +$7.53M 0.08% 184
2015
Q1 		– Sell
-700
Closed -$6K – 2225
2014
Q4 		$6K Hold
700
– – ﹤0.01% 1849
2014
Q3 		$16K Sell
700
-50
-7% -$4.76K ﹤0.01% 1874
2014
Q2 		$87K Buy
750
+50
+7% +$3.51K ﹤0.01% 1203
2014
Q1 		$897K Sell
700
-54
-7% -$4.28K 0.02% 441
2013
Q4 		$854K Buy
754
+63
+9% +$4.39K 0.02% 575
2013
Q3 		$755K Buy
691
+208
+43% +$16.6K 0.02% 627
2013
Q2 		$131K Buy
+483
New +$35.6K ﹤0.01% 1308

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wolverine Asset Management's VRTX Position: Q1 2025 in Review

Wolverine Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 19 shares — an estimated $7.65K sold.

Wolverine Asset Management first reported a position in VRTX in Q2 2013 and held it in 13 quarters. The position peaked at $7.29M in Q3 2014. 1,616 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Wolverine Asset Management reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Wolverine Asset Management sold 19 Vertex Pharmaceuticals shares in Q1 2025, an estimated $7.65K.
  • Wolverine Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • Wolverine Asset Management's Vertex Pharmaceuticals position peaked at $7.29M in Q3 2014.
  • 1,616 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Wolverine Asset Management's 13F filing for Q1 2025, filed 12 May 2025.